© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert oncologists share their perspectives on key updates in the management of hormone receptor–positive metastatic breast cancer from the past year.
October 4th 2022
Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.
Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.
October 11th 2022
Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].
In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.
October 18th 2022
Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.
Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.
October 25th 2022
Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.
Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.
November 1st 2022
Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.